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Abstract
Background: Antiretroviral therapy (ART) effectively decreases tuberculosis (TB) incidence long-term, but is associated with
high TB incidence rates in the first 6 months. We sought to determine the incidence and the long-term effects of TB during
ART on HIV treatment outcome, and the risk factors for incident TB during ART in a large urban HIV clinic in Uganda.
Methodology/Principal Findings: Routinely collected longitudinal clinical data from all patients initiated on first-line ART
was retrospectively analysed. 5,982 patients were included with a median baseline CD4+ T cell count (CD4 count) of
117 cells/mm
3 (interquartile range [IQR]; 42, 182). In the first 2 years, there were 336 (5.6%) incident TB events in 10,710
person-years (py) of follow-up (3.14 cases/100pyar [95% CI 2.82–3.49]); incidence rates at 0–3, 3–6, 6–12 and 12–24 months
were 11.25 (9.58–13.21), 6.27 (4.99–7.87), 2.47 (1.87–3.36) and 1.02 (0.80–1.31), respectively. Incident TB during ART was
independently associated with baseline CD4 count of ,50 cells/mm
3 (hazard ratio [HR] 1.84 [1.25–2.70], P=0.002) and male
gender (HR 1.68 [1.34–2.11], P,0.001). After two years on ART, the patients who had developed TB in the first 12 months
had a significantly lower median CD4 count increase (184 cells/mm
3 [IQR; 107, 258, n=118] vs 209 cells/mm
3 [124, 309,
n=2166], P=0.01), a larger proportion of suboptimal immune reconstitution according to two definitions (increase in CD4
count ,200 cells/mm
3: 57.4% vs 46.9%, P=0.03, and absolute CD4 count ,200 cells/mm
3: 30.4 vs 19.9%, P=0.006), and a
higher percentage of immunological failure according to the WHO criteria (13.6% vs 6.5%, P=0.003). Incident TB during ART
was independently associated with poor CD4 count recovery and fulfilling WHO immunogical failure definitions.
Conclusions/Significance: Incident TB during ART occurs most often within 3 months and in patients with CD4 counts less
than 50 cells/mm
3. Incident TB during ART is associated with long-term impairment in immune recovery.
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Introduction
The use of antiretroviral therapy (ART) causes major reductions
in HIV-associated morbidity and mortality, and decreases the risk
of developing tuberculosis (TB) by 70–90% [1–4]. This reduction
is time-dependent, however. Progressive immune reconstitution
decreases the risk of TB in the long-term, but there are high
incidence rates of TB early after ART initiation both in developed
countries and in resource-limited settings [5]. Incident TB during
ART is often due to ‘‘unmasking’’ of reactivated TB because of
restoration of TB antigen-specific functional immune responses. A
subset of these cases will have inflammatory symptoms consistent
with immune reconstitution inflammatory syndrome (IRIS) [6].
The high incidence of TB early during ART significantly
contributes to the high mortality rates early after ART initiation
reported in resource-limited settings [7–9]. Patients with very low
baseline CD4+ T cell counts (CD4 counts) are at higher risk for
unmasking TB as well as for dying early after ART initiation.
They are also more likely to have suboptimal immunological
recovery, which has been reported in both resource-rich and
resource-limited settings [10–15].
Suboptimal immune reconstitution affects up to 30% of all
patients initiated on ART [10,16]. Definitions vary, but immuno-
logical non-responders in developed countries are, in general,
identified by a ,30% increase in CD4 count or an absolute CD4
count ,200 cells/mm
3 with full suppression of HIV replication
during the first 6–12 months of ART [10]. Current CD4 counts
are the most important determinant of mortality after ART
initiation [13,17,18]. In developed countries, immunological non-
responders also have an approximately doubled relative risk of
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adequate response [10], although a study conducted in our own
clinic could not confirm these findings in a resource-limited setting
[11]. In addition, there was a recent report from Spain that
immunological non-responders also have a higher rate of non-
AIDS related mortality [19].
We sought to determine the incidence of, the risk factors for and
the long-term effects of incident TB on HIV treatment outcome in
a large urban HIV clinic in Uganda.
Methods
Setting
The Adult Infectious Diseases Clinic (AIDC) at the Infectious
Diseases Institute (IDI), at the Makerere University College of
Health Sciences in Kampala, provides outpatient care to over
20,000 registered HIV-positive patients since its inception in 2002.
Currently more than 10,000 patients are in active follow-up, of
whom over 8,000 have been initiated on ART. Treatment is based
on the national ART guidelines of the Ugandan Ministry of
Health, which, at the time of our study, consisted of daily co-
trimoxazole prophylaxis for all patients irrespective of CD4 count,
and ART initiation in those with a prior AIDS diagnosis (WHO
stage IV disease) or a CD4 count ,200 cells/mm
3 [20]. First-line
ART comprised of stavudine (d4T) or zidovudine (AZT) in
combination with lamivudine (3TC) plus a non-nucleoside reverse
transcriptase inhibitor in standard doses (nevirapine (NVP) or
efavirenz (EFV)). Choice of ART is at the physician’s discretion
and is also dependent on availability of the different first line
options. Clinical screening for active opportunistic infections
including TB takes place prior to ART initiation. Available
investigations for TB include fluorescence sputum microscopy,
chest radiology, abdominal ultrasonography, and fine-needle
aspiration of lymphadenopathy for acid fast bacilli microscopy
and cytology. Diagnosis of TB is made on the basis of these
investigations, but very often on clinical grounds. No mycobac-
terial culture facilities are available for routine evaluation. Patients
diagnosed with active TB are treated with a standard 8 month
regimen with a 8 week, 4 drug (isoniazid, rifampicin, ethambutol
and pyrazinamide) intensive phase and a subsequent 6 month, 2
drug (isoniazid, ethambutol) continuation phase. Scheduled clinic
appointments take place every 4 weeks with monitoring of clinical
status and adherence, CD4 counts are performed every 6 months
by FACS calibur (Becton Dickinson). Viral load monitoring
(Roche Amplicor, with a detection limit of 400 copies/mm
3) is not
routine and is only available for patients suspected of virological
failure on clinical and immunological grounds. Patients requiring
inpatient care are referred to Mulago National Referral Hospital,
a tertiary care hospital in the same complex. All treatment at the
IDI is free of charge.
Data collection and ethics statement
Data on clinical parameters, ART and adherence, WHO stage,
toxicities and opportunistic infections is routinely collected into a
database, to which laboratory data is added. A separate database
has recently been populated with pharmacy data on TB drug
prescriptions since 2006. A team of trained nurses and medical
officers verify data with the patient’s medical notes and audit this
database as part of regular clinic monitoring and evaluation. Use
of this database for clinical research has been approved by the
Institutional Review Boards (IRB) of IDI, Makerere University
and the Uganda National Council for Science and Technology.
The data for our study was extracted from this database and
analysed anonymously.
Study design and selection criteria
Incident TB (defined by the start of antituberculous therapy) in
the first 2 years after ART initiation was ascertained retrospec-
tively in all patients started on ART at IDI from January 2003 to
January 2009. Patients who initiated ART elsewhere were
excluded as well as patients initiated on second-line ART. Patients
with a history of active TB were excluded from the analysis (Figure
S1 and Table S1). The TB drug prescription database was merged
with the clinic database to validate the coding of new tuberculosis
after ART initiation (Figure S2). Patients coded as having
developed TB after ART initiation in both databases were
considered as TB cases. The TB status of cases identified in only
one of the two databases was ascertained by the validation team
after review of charts, confirming TB diagnosis by a clinician and
starting date of ART and TB treatment. This included all cases of
TB before initiation of the TB drug prescription database in 2006.
Patients whose charts were unavailable for review were excluded
from the analysis. Patients who were treated for TB after first-line
ART initiation were considered TB cases in the analysis, whether
they were diagnosed in our clinic or elsewhere, and whether the
diagnosis was based on bacteriological testing or clinical suspicion.
Definitions
Loss to follow-up after ART initiation was defined as no
documented clinic attendance for more than 90 days [21].
Immunological failure at 24 months was defined by fulfilment of
one or more of the World Health Organization (WHO) criteria:
decrease in CD4 count to pre-ART level or below, decrease in
CD4 count from on-treatment peak value by more than 50% or
persistent CD4 count ,100 cells/mm
3 [22]. For suboptimal
immune response at 24 months on ART, we used two previously
used definitions of a CD4 count increase of ,200 cells/mm
3 and
not attaining an absolute CD4 count .200 cells/mm
3 [11]. To
determine effects of TB on CD4 count, suboptimal immune
response and immunological failure at 24 months, we restricted
our analysis to patients who developed TB within 12 months after
ART initiation and to those who remained TB free during the
entire 24 months of follow-up to exclude patients on treatment for
active TB at the time that CD4+ T cell recovery was compared.
Statistical methods
TB incidence rates were calculated per 100 person years at risk
(pyar). Patients were censored at the time of TB diagnosis or at the
date of death, transfer or, in the case of loss-to-follow-up, date of
last visit, or the last visit date before January 2009. Risk factors
associated with the incidence of TB were analysed using a Cox
proportional hazards model. Differences in the median absolute
and median changes in CD4 counts and CD4 percentages at 24
months were compared between patients who never had TB and
those who did using the Mann-Whitney test, while the proportions
of immunological failure and suboptimal immune reconstitution
were compared between these two groups using chi-square tests.
Multiple linear regression models were fitted to investigate the
effect of incident TB during ART on CD4 count (absolute and
change from baseline) adjusting for baseline CD4 count, sex,
AZT-based regimen and age. For this, generalised estimating
equations were used to account for the intra-individual correlation
of repeated measurements. Robust standard errors and an
exchangeable correlation matrix with a linear link were employed.
Multivariable logistic regression analysis was performed to
investigate the effect of incident TB on immunological failure
adjusting for the same factors.
In all regression models risk factors were explored using
univariable regression analysis and were retained in the multivar-
TB-HIV Immune Reconstitution
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were included and confounders were retained based on univari-
able P,0.2. Interactions between variables were investigated and
tested using the likelihood ratio test, and were included in the
model if significant. All statistical tests were two-sided at an a value
of 0.05 and were conducted using STATA version IC 10.0
(College Station, Texas, USA).
Results
Patient characteristics and follow-up
A total of 5982 HIV-infected adults started on first line ART
between January 2003 and January 2009 were included. Baseline
characteristics of the included patients are shown in Table 1. The
majority of the patients were women (66.5%). The mean age of the
cohort was 37.2 years and the median baseline CD4 count was
117 cells/mm
3 (interquartile range [IQR]; 42, 182). Data on
baseline CD4 count and CD4 percentage were not available for
282 patients (16 of whom had incident TB). 96.8% of patients
were started on two nucleosides (NRTI) and a non-nucleoside
reverse transcriptase inhibitor (NNRTI).
Incident TB and risk factors
In the first two years of ART, there were 336 (5.6%) new TB
events in 10,710 person-years of follow-up (3.14 cases/100pyar
[95% CI 2.82–3.49]). Incidence rates of TB at 0–3, 3–6, 6–12 and
12–24monthswere11.25(9.58–13.21),6.27(4.99–7.87),2.47(1.87–
3.36) and 1.02 (0.80–1.31) cases/100pyar, respectively (Figure 1).
The multivariable Cox proportional hazards analysis showed that a
baseline CD4 count of ,50 cells/mm
3 (hazard ratio [HR] 1.84
[1.25–2.70], P=0.002) and male gender (HR 1.68 [1.34–2.11],
P,0.001) were significantly associated with an increased risk of TB.
Age per 10 years’ rise (HR 0.91 [0.79–1.04], P=0.17) and year of
ART initiation (HR 1.03 [0.93–1.14], P=0.55) were not associated.
Hazardratiosweresimilarwhentheanalysiswasdoneusingbaseline
CD4 count quartiles or including only patients with complete
baseline CD4 count data (data not shown).
Association between incident TB and immunological
response to ART
CD4 count (absolute and percentage) responses to ART in TB
cases were determined and compared with the responses observed
among those who remained free of TB. 2376 subjects with 24
months of follow-up data were available for analysis, of whom 123
(5.1%) had developed TB in the first 12 months on ART and 2209
(93.0%) who had remained TB-free after 2 years on ART. 44
(1.9%) patients developed TB between 12 and 24 months on
ART, these were excluded from the analysis. Data on their HIV
treatment outcome is summarised in Table S2. At two years, both
the median absolute CD4 count (269 cells/mm
3 [IQR; 179, 363]
vs 312 cells/mm
3 [221, 431], P=0.002) and the median CD4
count increase (184 cells/mm
3 [107, 258] vs 208 cells/mm
3 [123,
309], P=0.02) were significantly lower in the TB group. There
was no significant difference in median absolute or median change
in CD4 percentages: 17 (12, 22) vs 17 (13, 22), P=0.20 and 12 (7,
15) vs 10 (7, 14), P=0.51. The incident TB group had a larger
proportion of suboptimal immune reconstitution according to both
definitions: a CD4 count increase of ,200 cells/mm
3 after 24
months on ART (56.8% vs 47.1%, P=0.005) and not attaining an
absolute CD4 count .200 cells/mm
3 (30.1% vs 20.1%,
P,0.001). Multiple linear regression analysis using generalised
estimating equations of the factors associated with CD4 change at
two years confirmed that incident TB during ART was associated
with lower CD4 count recovery (b-coefficient [95% CI]; 2143.05
[2191.47–94.64], P,0.001). Poor CD4 count restoration was also
associated with male sex (Table 2). Higher baseline CD4 counts
were associated with a lower increase at two years. Effect
modification between sex and baseline CD4 count was found,
Table 1. Baseline characteristics.
Category Subcategory
All patients
(5982 [100%])
TB cases
(N=336 [5.6%])
Non-TB cases
(N=5646 [94.3%])
Sex (female) 3978 (66.5) 185 (55.1) 3793 (67.2)
Age (years, mean [SD]) 37.2 (8.7) 36.9 (8.7) 37.2 (8.7)
WHO stage
a I&II 2210 (37.1) 98 (29.2) 2112 (37.6)
III 2367 (39.7) 145 (43.2) 2222 (39.5)
IV 1380 (23.2) 93 (27.7) 1287 (22.9)
Baseline CD4 count
a (cells/mm
3, median [IQR]) 117 (42, 182) 85.5 (31.5, 153.5) 119 (43, 183)
Baseline CD4 count
a (cells/mm
3) $200 988 (17.3) 36 (11.3) 952 (17.7)
50–199 3140 (55.1) 172 (53.8) 2968 (55.2)
,50 1572 (27.6) 112 (35.0) 1460 (27.1)
Baseline CD4 percentage
a (median [IQR]) 7.0 (3.3, 11.4) 6.0 (3.0, 9.0) 7.0 (3.4, 11.8)
ART regimen d4T+3TC+NVP 3205 (53.6) 215 (64.0) 2990 (53.0)
d4T+3TC+EFV 75 (1.3) 9 (2.7) 66 (1.2)
AZT+3TC+NVP 351 (5.9) 11 (3.3) 340 (6.0)
AZT+3TC+EFV 2159 (36.1) 94 (28.0) 2065 (36.6)
Other 1st line
b 192 (3.2) 7 (2.1) 185 (3.3)
TB, tuberculosis; ART, antiretroviral therapy; IQR, interquartile range; d4T, stavudine; 3TC, lamivudine; NVP, nevirapine; AZT, zidovudine; EFV, efavirenz.
aData on CD4 count and CD4 percentage were not available for 282 patients (16 with incident TB); CD4 counts and percentages were closest recorded values to the
baseline start date, maximum 6 months pre and 15 days post ART initiation. Data on WHO stage were not available for 25 patients.
bOther first line triple ART regimens.
doi:10.1371/journal.pone.0010527.t001
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in men. Age and the use of an AZT-based regimen were not
associated with CD4 count change at 2 years. Results of multiple
linear regression analysis of the association of these factors with
absolute CD4 counts at 24 months were similar (data not shown),
with the exception of a positive effect of a higher baseline CD4
count which was to be expected. Trajectories of median CD4
counts over time in the two groups are shown in Figure 2.
Furthermore, a higher proportion of patients who developed TB
in the first 12 months after ART initiation could be classified as
immunological failure cases at 24 months according to the WHO
criteria than those who did not (13.0% vs 7.5%, P=0.001). This
effect was confirmed by multivariable logistic regression analysis
which showed a significantly increased likelihood of immunolog-
ical failure (odds ratio [OR]; 2.02 [1.13–3.59], P=0.02) with
incident TB, independent of baseline CD4 count, male sex, older
age and the use of AZT (Table 3).
Loss to follow-up and mortality
After two years on ART, 888 (14.8%) patients were lost to
follow-up and 596 (10.0%) had been transferred to a clinic
elsewhere. The median follow-up time was 603 days (IQR 196,
708). 363 (6.1%) patients died in the first two years of ART, with a
rate of 3.01 per 100 pyar (95% CI 2.71–3.35). Mortality rates for
0–3, 3–6, 6–12 and 12–24 months mirrored TB incidence rates:
10.05 (8.49–11.89), 4.76 (3.68–6.15), 2.89 (2.25–3.71) and 1.30
(1.05–1.61), respectively (Figure S3).
Discussion
Patients who developed TB after ART initiation in our large
urban ART cohort were more likely to have suboptimal immune
reconstitution despite TB treatment. Active TB in the first year
after ART initiation had long-lasting effects on immune
restoration: the median CD4 count change at 2 years was
significantly lower after correction for lower baseline CD4 count.
These patients also fulfilled the WHO criteria for immunological
failure more often. To our knowledge, the immunosuppressive
effect of incident active TB after ART initiation has not been
previously described.
The potential of virological and immunological response to
ART seems to be equal in both resource-rich and resource-limited
settings [12,16,23,24], although there are some reports that less
overall immune recovery occurs more often in resource limited
settings [14,23]. The most important factor associated with
suboptimal immune reconstitution in all settings is baseline CD4
count, but other factors have also shown to be associated, such as
higher baseline HIV viral loads, male sex, older age and hepatitis
C co-infection [10,16,25–30]. The use of AZT-based regimens has
also been implicated [11,31,32]. We were able to analyse and
identify an association with most of these factors in our study,
except for viral load and hepatitis C co-infection as our setting
does not allow for routine viral load and serologic testing. A higher
baseline CD4 count was associated with a lower CD4 increase
after two years of ART, which is consistent with previous reports
that show that patients with the lowest baseline CD4 count tend to
have the largest increase [33,34]. In multiple linear regression
analysis, the negative effect of incident TB during ART on
immune restoration was independently associated.
The underlying mechanisms of immunological non-response
are not completely understood, but it seems that a complex model
of immune activation, T cell turnover and homeostatic regulation
is responsible for CD4+ T cell loss [10]. Excessive T cell
destruction due to T cell activation plays an important role, and
has been shown to persist even after virological suppression occurs
[35–37]. Higher levels of T cell activation have been reported in
Figure 1. Tuberculosis incidence rates after ART initiation. TB
incidence rates according to time of TB occurrence post-ART. Point
estimates of incidence rates (cases/100pyar, [95% CI]): 0–3 months: 11.25
(9.58–13.21), 3–6 months: 6.27 (4.99–7.87), 6–12 months: 2.47 (1.87–3.36)
and 12–24 months: 1.02 (0.80–1.31). (ART, antiretroviral therapy; TB,
tuberculosis; CI, 95% confidence interval; pyar, person years at risk.)
doi:10.1371/journal.pone.0010527.g001
Table 2. Multiple linear regression of the relationship with CD4 change after 24 months of ART.
Subcategory b-Coefficient (95% CI) P-value
Incident TB after ART No 1
Yes 2143.05 (2191.47–94.64) ,0.001
Baseline CD4 count (cells/mm
3, per 50 cells’ rise) 223.38 (232.99–13.78) ,0.001
Sex Female 1
Male 248.04 (263.03–33.05) ,0.001
Interaction term baseline CD4 and sex 0.17 (0.05–0.29) 0.004
Age (years, per 10 years’ rise) 21.56 (25.92–2.79) 0.48
Regimen Non-AZT based 1
AZT-based 4.56 (21.64–10.76) 0.15
ART, antiretroviral treatment; TB, tuberculosis; CI, confidence interval; AZT, zidovudine.
doi:10.1371/journal.pone.0010527.t002
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frequent infections by various endemic pathogens, such as parasitic
infections. It has been suggested that co-infections might limit the
capacity for restoration of CD4 counts through an immunosup-
pressive effect on hematopoiesis and, most importantly, through
augmentation of the HIV-induced heightened immune activation
leading to widespread apoptosis of both HIV-infected and
uninfected lymphocytes [39,40]. In a small study done in Uganda,
the presence of co-infection with highly prevalent and endemic
pathogens in patients with and without ART was associated with
increased CD4+ T cell activation independent of CD4 count and
viral load [41]. Moreover, in another study done also in Uganda,
patients who developed an AIDS-defining condition according to
the WHO clinical staging system within 12 weeks pre or post ART
initiation, took longer to achieve an increase in CD4 count of
50 cells/mm
3 [42].
TB induced immunosuppression is a well-studied area: an
investigation of T cell cytokine responses in HIV-negative
pulmonary TB patients showed a persistent depressed tubercu-
lin-induced IFN-c response up to 18 months despite successful
treatment, suggesting a long-lasting depletion or primary dysfunc-
tion of antigen-responsive T cells from the peripheral blood due to
active TB [43]. Furthermore, apoptosis of Mycobacterium tuberculosis-
reactive CD4+ and non-CD4+ T cells seems to be increased in
pulmonary TB patients [44]. Taken together, these results suggest
that TB may have a long-lasting immunosuppressive effect, which
could account for the persistent decreased CD4 count levels we
found in our patients with incident TB. We hypothesize that the
co-infection leads to a long-lasting augmentation of already
heightened T cell activation in HIV-infected patients, followed
by increased apoptosis of CD4 cells with decreased immune
restoration.
Our data suggests that there may be a specific effect of incident
TB after ART initiation on immune recovery. A Malawian study
of 76 clinical ART failure cases showed that extrapulmonary TB
and Kaposi’s sarcoma were the most common conditions causing
misclassification compared to virologic failure gold standard, but
these factors were not significant in multivariable analysis [45].
Other studies have reported that AIDS events (including TB)
before or at the time of ART initiation are not associated with
decreased immune recovery [46–48], although the numbers of
patients analysed were small and this was not their primary study
objective. There has also been a report suggesting the contrary
[14]. In a study from South Africa, there was no effect on immune
recovery with prevalent and early incident TB together, although
a relatively low proportion (25%) of patients were analysable at 48
weeks of follow-up [49].
A recent paper published by Lawn and colleagues showed that
the time spent at lower CD4 count levels after ART initiation was
the predominant predictor of TB risk at 4 months of ART and
onwards in South Africa [50]. To address this issue in our cohort,
we restricted our analysis at 2 years after ART initiation to
compare CD4 counts of patients who initiated TB treatment
within the first 12 months of ART, and excluded all cases of active
(and thus also recurrent) TB. Therefore, our results do not
examine the duration of the effect of incident TB on immune
recovery. The poor CD4+ T cell reconstitution could also
represent a temporary delay in immune recovery followed by
the same recovery rate as non-TB patients as suggested by the
similarity in slope in figure 2. Patients with incident TB after ART
would still spend a significantly longer amount of time at lower
CD4 counts compared to patients who were TB free after ART.
As TB is the most frequent opportunistic infection in HIV-
infected patients in our setting, it is possible that the decreased
CD4 counts in patients after TB treatment may partly account for
the high rates of misclassification of treatment failure based on the
WHO immunological criteria, which have been reported in a
number of recent articles from sub-Saharan Africa [45,51–56].
The sensitivities of the WHO criteria ranged from 8% to 23% with
specificities from 90% to 98%. In our study, patients with incident
TB during ART were twice as likely to be classified as having
immunological failure after 2 years on ART than those without, a
finding which was confirmed in multivariable logistic regression to
be independent of other associated factors. Misclassification of
these patients as failing immunologically puts them at risk for
inappropriate switching to second line therapy. The immunosup-
Table 3. Multivariable logistic regression of immunological failure after 24 months on ART.
Odds Ratio (95% CI) P-value
Incident TB after ART 2.02 (1.13–3.59) 0.02
Baseline CD4 count (cells/mm
3, per 50 cells’ rise) 1.22 (1.14–1.30) ,0.001
Male sex 1.30 (0.93–1.82) 0.13
Age (years, per 10 years’ rise) 0.89 (0.73–1.08) 0.25
AZT-based regimen 1.61 (1.14–2.27) 0.007
ART, antiretroviral treatment; TB, tuberculosis; CI, confidence interval; AZT, zidovudine.
doi:10.1371/journal.pone.0010527.t003
Figure 2. Trajectories of median CD4 counts in the first two
years of ART by TB status. Patients with incident TB during ART
(triangles with dashed line) compared to patients who remained TB free
(circles with solid line) throughout the follow-up period. (ART,
antiretroviral treatment; TB, tuberculosis).
doi:10.1371/journal.pone.0010527.g002
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CD4 percent may be a better parameter to use in settings without
access to viral load confirmation of failure, although this data
highlights the need for more affordable and accessible viral load
testing [51–53,55].
Our large retrospective cohort study also reported comparable
incidence rates of ART-associated TB to those published from
earlier work in high-endemic areas [5,57–59]. As expected,
incident TB during ART was a common occurrence in our study.
Incidence rates were very high in the first three months, and
decreased to a level which was still almost three fold higher than in
the general Ugandan population [60]. Mortality rates after ART
initiation mirrored these rates. Identified risk factors for develop-
ing TB after ART initiation in our cohort were a low baseline
CD4 count and male sex (both have been previously described
[5,57–59,61]) and highlight the importance of initiating ART
earlier.
Our study had several limitations. Because of the retrospective
design the data was often incomplete, although we validated our
datawithchart reviews. We excluded a large numberof possible TB
cases that could not be verified by chart review which may have
introduced bias. Although our population was large, the presented
data was collected at only one centre, possibly affecting the
generalisability of our results. We are also aware of the possible
under- and over-diagnosis of TB in our setting since mycobacterial
culture is not routinely used to confirm cases of smear-negative TB
which are frequent in HIV-positive populations. We do feel that our
setting reflects the current practice in many clinics in sub-Saharan
Africa. Finally,an alternative explanationforthe lower CD4+ T cell
count levels in patients with incident TB during ART is decreased
adherence to ART during TB treatment due to high pill burden,
and side-effects [32]. This may have lead to lower adherence levels
and thus slower immune recovery. Insensitive measurements of
adherence in our clinic (self-report and pill counts) in combination
with infrequent viral load testing made it difficult to exclude this
possibility. Nonetheless, the majority of the TB patients who
developed suboptimal immune reconstitution for whom a viral load
was measured (6 of 8 patients) had an undetectable viral load.
In conclusion, in this large urban HIV clinic in Uganda the
incidence of TB is very high in the first three months after ART
initiation, especially in patients with very low CD4 counts, and
likely contributes to high early mortality. Furthermore, incident
TB after ART may have a long-lasting effect on immune recovery
which, in turn, is associated with a higher risk of opportunistic
infections, mortality and non-infectious complications of AIDS.
The biologic importance of our finding of suboptimal CD4
recovery in patients with incident TB during ART in terms of
virologic failure is unknown, and warrants further prospective
investigation. Finally, ART effectively decreases TB incidence long
term. Our findings highlight the importance of implementing
strategies to initiate ART earlier in sub-Saharan Africa to decrease
ART-associated active TB.
Supporting Information
Figure S1 Flowchart of patient selection for analysis. Of all
patients initiated on first-line ART, patients with a history of active
TB were excluded from the analysis. The remaining patients were
followed up for development of incident TB in the first two years
after ART initiation. The patients who had not died, were not
transferred to another clinic or were lost to follow-up, and had
CD4 counts available at 24 months after ART initiation, were
selected for comparison of HIV treatment outcomes (box). (TB,
tuberculosis; ART, antiretroviral treatment)
Found at: doi:10.1371/journal.pone.0010527.s001 (0.25 MB TIF)
Figure S2 Flowchart of post-ART tuberculosis case selection for
analysis. The TB drug database was merged with the clinic
database to identify post-ART TB cases. Cases coded as having
developed TB after ART initiation in both databases were
considered as definite TB cases. The TB status of cases identified
in only one of the two databases was ascertained by the validation
team after review of charts, confirming TB diagnosis and starting
date of ART and TB treatment. Unavailability of the chart for
review led to exclusion from the analysis. TB in participants
occurring after first-line ART initiation were considered as TB
cases in the analysis, whether they were diagnosed in our clinic or
elsewhere, and whether the diagnosis was based on bacteriological
testing or clinical suspicion.
Excluded after chart review:
a no diagnosis of TB (51), TB before
ART initiation (64), TB drugs and ART initiated on the same date
(2) and chart unavailable for review (65);
b history of previous TB
(7);
c chart unavailable for review (7).
(TB, tuberculosis; ART, antiretroviral treatment)
Found at: doi:10.1371/journal.pone.0010527.s002 (0.32 MB TIF)
Figure S3 Mortality rates after ART initiation. Mortality rates
after ART initiation mirror those of the TB incidence with the
highest rates in the first 3–6 months. Point estimates of mortality
rates (cases/100pyar, [95% CI]): 0–3 months: 10.05 (8.49–11.89),
3–6 months: 4.76 (3.68–6.15), 6–12 months: 2.89 (2.25–3.71) and
12–24 months: 1.30 (1.05–1.61). (TB, tuberculosis; ART,
antiretroviral therapy; CI, confidence intervals; pyar, person years
at risk)
Found at: doi:10.1371/journal.pone.0010527.s003 (0.64 MB
TIF)
Table S1 Baseline characteristics of all patients started on first-
line ART. TB, tuberculosis; ART, antiretroviral therapy; IQR,
interquartile range; d4T, stavudine; 3TC, lamivudine; NVP,
nevirapine; AZT, zidovudine; EFV, efavirenz.
a Data on WHO stage, CD4 count and CD4 percentage were not
available for some patients; CD4 counts and percentages were
closest recorded values to the baseline start date, maximum 6
months pre-ART.
b Other first line triple ART regimens.
Found at: doi:10.1371/journal.pone.0010527.s004 (0.05 MB
DOC)
Table S2 HIV treatment outcome after 2 years of ART. HIV
treatment outcomes in TB cases were determined for all patients
with 24 months of follow-up data available. Outcomes were
compared between patients who developed TB in the first 12
months on ART, in months 12–24 on ART and the patients who
had remained TB-free after 2 years on ART. To determine effects
of TB on CD4 count, suboptimal immune response and
immunological failure at 24 months, we restricted our analysis to
patients who developed TB within 12 months after ART initiation
and to those who remained TB free during the entire 24 months of
follow-up to exclude patients on treatment for active TB at the time
that CD4 T cell recovery was compared.
aClosest recorded values to 24 months after ART initiation (minimum
21 months and maximum 27 months).
b Data on CD4 count change and CD4 percentage change were
not available for 49 and 291 patients, respectively. Suboptimal
immune response according to the definition of increase ,
200 cells/mm
3 was not determinable in these patients.
c According to the World Health Organization criteria: decrease
in CD4 count to pre-ART level or below, decrease in CD4 count
from on-treatment peak value by more than 50% or persistent
TB-HIV Immune Reconstitution
PLoS ONE | www.plosone.org 6 May 2010 | Volume 5 | Issue 5 | e10527CD4 count ,100 cells/mm
3. ART, antiretroviral treatment; TB,
tuberculosis; IQR, interquartile range.
Found at: doi:10.1371/journal.pone.0010527.s005 (0.03 MB
DOC)
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